BLCM - Bellicum Pharmaceuti...About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
| Previous Close | $4.56 | Open | |
| Volume | Market Cap | 93.86M | |
| Yield | Last Dividend |
| Amid a record bad year, Bellicum keeps t... | 12/07/20 |
| It???s been no less than a disastrous year for Houston biotech Bellicum Pharmaceuticals after taking a scalpel to its pipeline and dumping a vast majo... | |
| Recent Updates on Hemophagocytic Lymphoh... | 11/18/20 |
| Global Hemophagocytic Lymphohistiocytosis Market report brings into light key market dynamics of the sector. It provides guidelines about planning of ... | |
| The Daily Biotech Pulse: Lilly's COVID-1... | 11/10/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 9) Alco... | |
| The Daily Biotech Pulse: Alzheimer's Con... | 11/04/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 3) Bio-... | |
| Bellicum Pharmaceuticals Announces Closi... | 11/03/20 |
| Share this Stock Information HOUSTON, Nov. 03, 2020 (GLOBE NEWSWIRE) ??? Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, c... | |
| Bellicum Pharmaceuticals to cut 79% of s... | 10/30/20 |
| Shares of Bellicum Pharmaceuticals Inc. undefined plunged 35.1% in midday trading Friday, putting them on track for their biggest-ever one-day drop, a... | |
| Zacks: Brokerages Expect Bellicum Pharma... | 10/24/20 |
| Wall Street brokerages expect Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) to post earnings of ($3.29) per share for the current fiscal quarter, Zacks r... | |
| -$3.29 EPS Expected for Bellicum Pharmac... | 10/22/20 |
| Equities analysts expect that Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) will announce earnings per share of ($3.29) for the current quarter, Zacks re... | |
| Global CAR-T Therapy Treatment Market Is... | 10/03/20 |
| Data Bridge Market Research has recently added a concise research on the Global CAR-T Therapy Treatment Market to depict valuable insights related to ... | |
| Tumor Infiltrating Lymphocytes Market Ty... | 09/30/20 |
| Tumor Infiltrating Lymphocytes Market report gives key measurements, status of the manufacturers and is a significant source of direction for the busi... | |
| Here is What Hedge Funds Think About Bel... | 06/12/20 |
| In this article you are going to find out whether hedge funds think Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) is a good investment right now. We like... | |
| All You Need to Know About Bellicum Phar... | 05/22/20 |
| Bellicum Pharmaceuticals (BLCM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank ... | |
| The Daily Biotech Pulse: Roche Obtains F... | 03/13/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 12.) ... | |
| The Daily Biotech Pulse: NY State Endors... | 03/11/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 10)... | |
| The Daily Biotech Pulse: Mesoblast To Te... | 03/10/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 9.) A... | |
| Bellicum Pharmaceuticals to Present New ... | 01/16/20 |
| HOUSTON, Jan. 16, 2020 -- Bellicum Pharmaceuticals, Inc. , a leader in developing novel, controllable cellular immunotherapies for cancers, today anno... | |
| Short Interest in Bellicum Pharmaceutica... | 11/16/19 |
| Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) was the recipient of a significant growth in short interest during the month of October. As of October 31st... | |
| Earnings Preview: Bellicum Pharmaceutica... | 10/29/19 |
| Bellicum Pharmaceuticals (BLCM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Ge... | |
| The Daily Biotech Pulse: Roche Snags Dou... | 08/16/19 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 15) ... | |
| The Daily Biotech Pulse: Glaukos To Buy ... | 08/08/19 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 7) A... | |
| The Daily Biotech Pulse: Novartis Stands... | 08/07/19 |
| Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 6) A... | |
| The Daily Biotech Pulse: Sanofi's Dupixe... | 08/06/19 |
| Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks No biotech stocks hit 52-week highs Monday. Down I... | |
| The Daily Biotech Pulse: Jounce Jumps On... | 07/24/19 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 23) ... | |
| The Daily Biotech Pulse: Vertex Bets Big... | 06/07/19 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 6) B... | |
| Bellicum Pharmaceuticals (BLCM) May Repo... | 05/07/19 |
| Bellicum Pharmaceuticals (BLCM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Ge... | |
| Bellicum Pharmaceuticals beats by $0.03,... | 05/07/19 |
| Bellicum Pharmaceuticals (BLCM): Q1 GAAP EPS of -$0.55 beats by $0.03. Revenue of $0.52M (+246.7% Y/Y) beats by $0.34M. Press Release | |
| Bellicum Pharmaceuticals, Inc.'s (BLCM) ... | 03/12/19 |
| No summary available. | |
| Bellicum Pharmaceuticals beats by $0.02,... | 03/12/19 |
| No summary available. | |
| FDA finalizes guidance for expedited rev... | 02/15/19 |
| No summary available. | |
| Oncology players in the red on Celgene d... | 01/03/19 |
| No summary available. | |
| Hold rating | 10/30/20 |
| Wells Fargo downgrades from Overweight to Equal-Weight rating and announces Price Target of $4.50 | |
| Date | 04/12/2019 (AMC) | Est. (EPS/Rev.) | $1.37 |
| Actual (EPS/Rev.) | $2.5B | EPS (TTM) | $??? |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| Lewis Aung's long pick | Kyaw Aung | 69.00 % | Subscribe |
| Mojo Day Trading | ProTrader Mike | 46.00 % | Subscribe |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
